Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

5 februari 2021 uppdaterad av: Zhenyu Zhang, The First Affiliated Hospital of Zhengzhou University

MR and Histopathology Images Based Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas Using Artificial Intelligence

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Effective treatment for recurrent gliomas is still challenging. Malignant gliomas are considered to be one of the most angiogenic cancers and are mostly sustained by vascular endothelial growth factor (VEGF) signaling via its endothelial tyrosine kinase receptor VEGF receptor 2 (VEGFR-2). Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits VEGFR-2. Apatinib has been demonstrated as monotherapy that prolongs OS in patients with gastric cancers after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse effects. This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study also seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas. The creation of a registry for patients with recurrent gliomas treated by Apatinib with detailed survival data, radiological data, histopathology image data and with sufficient sample size for artificial intelligence provides opportunities for personalized prediction of responses to Apatinib.

Studietyp

Observationell

Inskrivning (Förväntat)

600

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Henan
      • Zhengzhou, Henan, Kina, 450052
        • Rekrytering
        • Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 90 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Subjects are all received anti-angiogenesis drug (Apatinib) in the First Affiliated Hospital of Zhengzhou University.

Beskrivning

Inclusion Criteria:

  1. Adult patients with histologically-confirmed WHO Grade II-IV gliomas which have recurrent or progressive conditions.
  2. With measurable or evaluable disease defined by RANO criteria by MRI scan.
  3. Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2
  4. Life expectancy ≥3 months.
  5. No evidence of serious cardiopulmonary function damage, postoperative complication and hemorrhage on the baseline.
  6. No history of serious hypertension disease.
  7. Patients have adequate organ function as defined by the following criteria:

    • Hemoglobin (HGB) ≥90g/L
    • Absolute neutrophil count (ANC) ≥1.5×109/L
    • White blood cell (WBC) ≥3.0×109/L
    • Platelet count ≥80×109/L
    • Alanine aminotransferase(ALT) and Aspartate aminotransferase (AST) of ≤2.5 upper normal limitation (UNL) or ≤5 UNL in case of liver metastasis
    • Creatinine (Cr) of ≤1.25 UNL or creatinine clearance(Ccr) > 45 ml/min.
  8. With written informed consent signed voluntarily by patients themselves.

Exclusion Criteria:

  1. Patients with age<18 or >90 years.
  2. Pregnant or lactating women.
  3. Inadequately controlled hypertension (defined as systolic blood pressure > 140 and/or diastolic blood pressure > 90 mmHg on antihypertensive medications).
  4. New York Heart Association (NYHA) Grade II or greater congestive heart failure.
  5. Factors that could have an effect on oral medication.
  6. Abnormal Coagulation (international normalized ratio>1.5, prothrombin time>UNL+4s,activated partial thromboplastin time>1.5 UNL), with tendency of bleeding.
  7. Currently receive thrombolytic and anticoagulation therapy
  8. History of pneumorrhagia(CTCAE grade ≥2 ) or other parts hemorrhage(CTCAE grade ≥3 ) within 4 weeks prior to treatment.
  9. History of artery thrombosis and phlebothrombosis, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, within 6 month prior to treatment.
  10. Medical history of clinically significant thrombosis (bleeding or clotting disorder), excluding warfarin(1mg po qd) and aspirin(80-100mg po qd) for prevention under INR≤1.5.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Apatinib
Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes of Response to Treatment
Tidsram: From enrollment to progression of disease. Estimated about 6 months
Response were evaluated with Response Assessment in Neuro-Oncology (RANO) criteria every 1 month after treament.
From enrollment to progression of disease. Estimated about 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression-Free Survival (PFS)
Tidsram: From enrollment to progression of disease. Estimated about 6 months.
The length of time from enrollment until the time of progression of disease (PFS, progression-free survival)
From enrollment to progression of disease. Estimated about 6 months.
Overall Survival (OS)
Tidsram: From enrollment to death of patients. Estimated about 1 year.
The length of time from enrollment until the time of death (OS, overall survival)
From enrollment to death of patients. Estimated about 1 year.
Incidence of treatment-related adverse events
Tidsram: Time Frame: 0 to 1 year
The incidence of treatment-related adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Time Frame: 0 to 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 januari 2018

Primärt slutförande (Förväntat)

1 januari 2025

Avslutad studie (Förväntat)

1 juni 2025

Studieregistreringsdatum

Först inskickad

31 december 2019

Först inskickad som uppfyllde QC-kriterierna

31 december 2019

Första postat (Faktisk)

2 januari 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

8 februari 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 februari 2021

Senast verifierad

1 februari 2021

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

IPD-planbeskrivning

Undecided

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera